[新聞] WHO的團體疫苗試驗聲明

作者: skbb2553 (HS)   2021-10-26 23:44:21
完整標題:WHO Statement on Solidarity Trial Vaccines
發稿單位:WHO(世界衛生組織)
發稿時間:26 October 2021
撰 稿 者:同發稿單位
原文連結:https://bit.ly/3pC2Qyz
WHO and the Ministries of Health of Colombia, Mali, and the Philippines
announce the launch of the co-sponsored Solidarity Trial Vaccines.
關於Solidarity Trail的進一步介紹:https://bit.ly/3jEEQXL
WHO將會資助哥倫比亞衛生部、馬利衛生部、菲律賓衛生部進行團體疫苗試驗
This is an international, randomized clinical trial platform designed to
rapidly evaluate the efficacy and safety of promising new candidate vaccines
selected by an independent vaccine prioritization advisory group composed of
leading scientists and experts.
這是一個國際性、隨機性臨床試驗平台,目的是
經由專業人士和科學家組成的獨立疫苗專家小組選擇新的候選疫苗
並盡快評估安全性和有效性
This announcement comes after the relevant regulatory authorities and ethics
committees have granted approval for the study to progress.
The national principal investigators and their research teams in Colombia,
Mali, and the Philippines have begun recruiting volunteers joining the trial.
本次聲明經由當地相關法律單位和倫理審議委員會審核通過後提出。
臨床試驗主負責人和所屬研究團隊開始應徵受試者做臨床試驗。
The Solidarity Trial Vaccines is beginning with research teams in over 40
trial sites spread across the three countries. National research teams bring
together experienced investigators well-versed in good clinical practice and
the conduct of clinical trials.
團體疫苗試驗將會在三個國家、共40個臨床試驗點進行臨床試驗。
(National research那一句講會做好臨床試驗但我不太會翻)
To date, the independent vaccine prioritization advisory group has reviewed
the evidence of around 20 candidate vaccines. Following the recommendation of
the working group, 2 candidate vaccines are now included in the Solidarity
Trial Vaccines. These are a protein subunit vaccine from Medigen, and a DNA
vaccine encoding the spike protein from Inovio.
到目前為止,獨立疫苗專家小組已經確認約20個候選疫苗的相關證據
經小組建議,把高端的次蛋白疫苗和Inovio的DNA疫苗加入團體疫苗試驗
Two additional vaccines are expected to enter the Solidarity Trial Vaccines
once additional evidence and documentation has been reviewed and accepted as
satisfactory by the independent vaccine prioritization advisory group.
It is expected that other candidate vaccines currently under consideration by
the vaccine prioritization advisory group may be added to the trial in late
2021 and during 2022.
只要相關證據都能證明的話,預期2021年底至2022年還會再加入2支候選疫苗
The Solidarity Trial Vaccines aims to accelerate the evaluation of multiple
promising candidate COVID-19 vaccines, contributing to the creation of a
larger portfolio of vaccines needed to protect people from COVID-19 around
the world. The trial has the additional potential to uncover
second-generation vaccines with greater efficacy, conferring greater
protection against variants of concern, offering longer duration of
protection, and/or using needle-free routes of administration.
(團體疫苗試驗的聲明和目標 整段省略不提應該可以吧....0_0?)

Links booklink

Contact Us: admin [ a t ] ucptt.com